> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Celltrion’s Humira Biosimilar Now Interchangeable: FDA
- URL: https://www.fdaweb.com/celltrions-humira-biosimilar-now-interchangeable-fda/
- Published: 2025-04-16T12:00:00.000Z
- Updated: 2026-09-14T15:09:41.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5159018

FDA has granted interchangeable biosimilar status to Celltrion’s Yuflyma (adalimumab-aaty), a high-concentration, citrate-free biosimilar copy of AbbVie’s Humira. The designation permits pharmacists to substitute Yuflyma for Humira without requiring a new prescription from a healthcare provider. The original Yuflyma BLA was approved 5/2023 for treating eight conditions.